The role of Alimta in the treatment of malignant pleural mesothelioma: An overview of preclinical and clinical trials

Lung Cancer

Volumn 45, Issue SUPPL., 2004, Pages

  Hanauske, Axel Rainer ^a  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

Alimta; Chemotherapy; Cisplatin; Malignant pleural mesothelioma; Multitargeted antifolate; Pemetrexed; Vitamin supplementation

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FOLIC ACID ANTAGONIST; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED;

ADVANCED CANCER; ASTHENIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEMATOLOGIC DISEASE; HUMAN; MALIGNANT MESOTHELIOMA; MUCOSA INFLAMMATION; MUSCLE FATIGUE; NAUSEA; NEUTROPENIA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RANDOMIZATION; RASH; STOMATITIS; THROMBOCYTOPENIA; VITAMIN SUPPLEMENTATION; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; CISPLATIN; CLINICAL TRIALS; GLUTAMATES; GUANINE; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 3142657184     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.04.021     Document Type: Conference Paper

References (23)

1. Chahinian A.P., Pajak T.F., Holland J.F., Norton L., Ambinder R.M., Mandel E.M. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann. Intern. Med. 96:1982;746-755
2. Yates D.H., Corrin B., Stidolph P.N., Browne K. Malignant mesothelioma in south east England: Clinicopathological experience of 272 cases. Thorax. 52:1997;507-512
3. Ong St., Vogelzang N.J. Chemotherapy in malignant pleura mesothelioma: a review. J. Clin. Oncol. 14:1996;1007-1017
4. Ryan C.W., Herndon J., Vogelzang N.J. A review of chemotherapy trials for malignant mesothelioma. Chest. 113:1998;66S-73S
5. Alberts A.S., Falkson G., Goedhals L., Vorobiof D.A., Van der Merwe C.A. Malignant pleura mesothelioma: A disease unaffected by current therapeutic maneuvers. J. Clin. Oncol. 6:1988;527-535
6. Rusthoven J.J., Eisenhauer E., Butts C., Gregg R., Dancey J., Fisher B., et al. Multitrargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 17:1999;1194
7. John W., Picus J., Blanke C.D., Clark J.W., Schulman L.N., Rowinsky E.K., et al. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer. 88:2000;1807-1833
8. Miles D.W., Smith I.E., Coleman R.E., et al. A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur. J. Cancer. 37:2001;1366-1371
9. Schultz RM, Chen VJ, Bewley JR, Roberts EF, Shin C, Dempsey JA. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 1999 (Suppl 6);26:68-73.
10. Mendelsohn L.G., Shih C., Chen V.J., Habeck L.L., Gates S.B., Shackelford K.A. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin. Oncol. 26(Suppl 6):1999;42-47
11. Moran R.G. Roles of folypoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin. Oncol. 26(Suppl 6):1999;24-32
12. Teicher BA, Alvarez E, Liu P, Lu K, Menon K, Dempsey J, Schultz RM. MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. Semin Oncol 1999;26(2 Suppl 6):55-62.
13. Teicher B.A., Chen V., Shih C., Menon K., Forler P.A., Phares V.G., et al. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin. Cancer Res. 6(3):2000;1016-1023
14. Tonkinson J.L., Worzalla J.F., Teng C.H., Mendelsohn L.G. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res. 59(15):1999;3671-3676
15. McDonald A.C., Vasey P.A., Adams L., Walling J., Woodworth J.R., Abrahams T., et al. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin. Cancer Res. 4:1998;605-610
16. Rinaldi D.A., Burris H.A., Dorr F.A., Woodworth J.R., Kuhn J.G., Eckhardt S.G., et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J. Cin. Oncol. 13:1995;2842-2850
17. Rinaldi D.A., Kuhn J.G., Burris H.A., Dorr F.A., Rodriguez G., Eckhardt S.G., et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administerd every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother. Pharmacol. 44:1999;372-380
18. Fossella F.V., Gatzemeier U. Phase I trails of pemetrexed. Semin. Oncol. 29(Suppl. 5):2002;8-16
19. Thödtmann R., Depenbrock H., Blatter J., Johnson R.D., van Oosterom A., Hanauske A.R., et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY 231514) in combination with cisplatin. J. Clin. Oncol. 17:1999;3009-3016
20. Calvert A.H., Hughes A.N., Calvert P.M. Alimta in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial. Lung Cancer. 29(Suppl. 2):2000;73-74
21. Scagliotti G.V., Shin D.M., Kindler H.L., Vasconcelles M.J., Keppler U., Manegold C., et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as fornt-line therapy in malignant pleural mesothelioma. J. Clin. Oncol. 21:2003;1556-1561
22. Niyikiza C., Baker S.D., Seitz D.E., Walling J.M., Nelson K., Rusthoven J.J., et al. Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther. 1:2002;545-552
23. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21:2003;2636-2644